NCT01837095 - Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions

Metastatic Breast Cancer

Interventions

DRUG

POL6326

POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin

Trial Locations (12)

Weill Cornell Breast Center, New York

HGUG Marañón, Madrid

Hospital 12 de Octubre, Madrid

Vanderbilt University School of Medicine, Nashville

Hospital Cinico Universitario de ValenciaValencia, Valencia

Washington University School of Medicine, Division of Oncology, St Louis

St Luke's Cancer Institute, Kansas City

'Dartmouth-Hitchcock Medical Center, Lebanon

Hospital del Mar, Barcelona

Hospital Quiron Barcelona, Barcelona

Hospital Vall d'Hebrón, Barcelona

Instituto Catalàn de Oncologia L'Hospitalet, L'Hospitalet de Llobregat